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ABSTRACT 
Objective: Histone deacetylase inhibitors (HDACi) have four essential pharmacophores as cap group, connecting unit, a linker moiety and zinc 
binding group for their anticancer and histone deacetylase (HDAC) inhibition activity. On the basis of this fact, the objective of this research was to 
evaluate the exact role of pyrazole nucleus as connecting unit and its role in the development of newer HDACi. 
Methods: Ligand and structure-based computer-aided drug design strategies such as pharmacophore and atom based 3D QSAR modelling, 
molecular docking and energetic based pharmacophore mapping have been frequently applied to design newer analogs in a precise manner. Herein, 
we have applied these combinatorial approaches to develop the structure-activity correlation among novel pyrazole-based derivatives. 
Results: the Pharmacophore-based 3D-QSAR model was developed employing Phase module and e-pharmacophore on compound 1. This 3D-QSAR 
model provides fruitful information regarding favourable and unfavourable substitution on pyrazole-based analogs for HDAC1 inhibition activity. 
Molecular docking studies indicated that all the pyrazole derivatives bind with HDAC1 proteins and showed critical hydrophobic interaction with 
5ICN and 4BKX HDAC1 proteins.  
Conclusion: The outcome of the present research work clearly indicated that pyrazole nucleus added an essential hydrophobic feature in cap group 
and could be employed to design the ligand molecules more accurately. 
Keywords: 3D-QSAR, e-pharmacophore mapping, Ligand and structure-based designing, Docking, Pyrazole analogs 




Ligand and structure-based computer-aided drug design strategies 
includes several computational approaches that have been 
repeatedly applied to design and discover the new molecules. 
Practically, neither single ligand-based nor structure-based drug 
design strategy approach is unable to fulfil the needs of drug 
discovery and development [1-6]. Vorinostat (SAHA) (fig. 1) and 
other HDACi hamper different classes of histone deacetylases 
(HDACs) by interacting with the active pocket site of HDAC proteins 
leading to interfere with different tumor mediators. All these HDACi 
have four essential structural elements such as a surface recognition 
cap group, a connecting unit, a linker moiety and a zinc-binding 
domain (ZBD). The connection of aromatic cap group with linker 
moiety in HDACi is essential for HDAC inhibitory activity [7, 8]. The 
substitution of amide connecting unit of SAHA with a heterocyclic 
nucleus has resulted in the development of SAHA like analogs. These 
substituted derivatives possess HDAC inhibitory activity against a 
variety of HDAC classes, indicating that heterocyclic nucleus as 
connecting unit retains the essential characteristic required for 
activity [9-15]. The key intention of the present study was to apply 
the structure and ligand-based tactics to recognize the importance of 
heterocyclic connecting unit at SAHA analogs. This study consists of 
numerous consecutive steps such as preparation of data set, the 
establishment of structure-activity relationship by 3D QSAR 
approach, molecular docking of ligands in the active site of a protein 
molecule, e-pharmacophore mapping and establishment of a 
correlation between structure and biological activity. 
 
 
Fig. 1: Vorinostat (SAHA) and its pyrazole analogs 
 
MATERIALS AND METHODS 
Biological data 
A set of 24 pyrazoles based SAHA analogs with HDAC1 inhibition 
activity was taken from literature to create biological dataset (table 
1) as to determine the role of pyrazole nucleus as connecting unit in 
place of amide group in SAHA [16]. The dataset was collected from 
single laboratory report.  
The IC50 value of analogs was transformed into negative logarithm of 
IC50 (pIC50) values by using formula, pIC50 = 6-log IC50 (µm). 
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Ligand preparation  
The structures of pyrazole-based SAHA analogs were drawn using 
ChemDraw Ultra/Chem 3D software, cleaned, optimized and 
prepared using Ligprep v2.5 (Schrodinger, LLC, New York). This 
procedure basically involved various sequential steps such as 
preparation of 3D structures from 2D representation, development 
of ionization state at pH 7.0±2, elimination of rebellious structures, 
generation of isomers, the addition of omitted hydrogen atoms and 
energy minimization by OPLS_2005 force field [17]. 
 
Table 1: Biological dataset of pyrazole-based SAHA analogs 
 
Comp. No. R2 R3 R4 R5 R6 n HDAC1 
IC50 (µm) 
PIC50 
A-1 H H H H H 1 0.32 6.49 
A-2 H H C(CH3)3 H H 1 1.31 5.88 
A-3 H H CH3 H H 1 0.323 6.49 
A-4 H H Br H H 1 0.218 6.66 
A-5 H H NO2 H H 1 0.242 6.62 
A-6 H H CF3 H H 1 0.197 6.71 
A-7 H H F H H 1 0.293 6.53 
A-8 H OCH3 H H H 1 0.342 6.47 
A-9 H Br H H H 1 0.068 7.17 
A-10 H Cl F H H 1 0.116 6.94 
A-11 F H F H H 1 0.539 6.27 
A-12 H H C6H5 H H 1 0.033 7.48 
A-13 H C6H5 H H H 1 0.064 7.19 
A-14 H H 
 
H H 1 0.376 6.42 
A-15 H H C6H5CH2O H H 1 0.067 7.17 
A-16 H H C6H5O H H 1 0.086 7.07 
A-17 H H 
 
H H 1 0.075 7.12 
A-18 H H C6H5NH H H 1 0.035 7.46 
A-19 H C6H5NH H H H 1 0.145 6.84 
A-20 H C6H5O H H H 1 0.719 6.14 
A-21 H H C6H5 H H 2 0.227 6.64 
A-22 H H C6H5 H H 3 0.233 6.63 
A-23 H H C6H5 H H 4 2.66 5.58 
A-24 H H C6H5 H H 5 2.49 5.60 
 
Pharmacophore and atom based 3D QSAR modelling 
3D QSAR modelling methods are being gradually employed for lead 
discovery, optimization and understanding the interactions between 
the drug and the receptor molecules. The development of structure-
activity correlation and 3D QSAR models were achieved using 
‘PHASE’v3.4 (Schrodinger, LLC, New York) [18]. Common 
pharmacophore hypothesis was produced using Phase module 
which initially involved clean-up of ligands and generation of 
conformers through the use of OPLS_2005 force field [19]. After the 
generation of conformers, sites were created which provided 
possible common pharmacophore features such as ADNHR; where A, 
D, N, H, R and P stands for hydrogen bond acceptor, hydrogen bond 
donor, negatively charged group, a hydrophobic group, an aromatic 
ring and positively charged group, respectively. PHASE correlated 
and categorized the activities of ligand molecules into active, 
moderately active and inactive molecules employing volume, vector, 
and site score. Furthermore, on the basis of the alignment of these 
molecules PHASE developed 3D pharmacophores as common 
feature hypotheses [20]. These pharmacophores were analyzed 
using survival, survival minus inactive and posthoc scoring 
techniques to determine best suitable common pharmacophore 
hypothesis. The high scored common pharmacophore hypothesis 
was selected for alignment and further 3D-QSAR studies. The leave 
one out (LOO) method was adopted to generate and validate an 
effective 3D-QSAR model. The suitability of the 3D-QSAR models was 
determined by analyzing the various parameters including 
regression coefficient (>0.6), a minute standard deviation, elevated 
variance ratio, high stability score, low RMSE value and high Pearson 
R-value [19-21]. The appropriate hypothesis was selected in the 
Score Hypotheses step by selecting the different training and test 
sets, and visualizing the model results which provided fruitful 
outcomes to investigate the optimization of core structures [20, 21]. 
Docking method  
Molecular docking studies were accomplished using Glide 
v5.8 (Schrodinger, LLC, New York, NY) which involved three 
sequential steps as preparation of protein molecule, generation of 
receptor grid, docking of ligands with protein [22]. The protein 
preparation step involved the acquirement of crystallized HDAC 
protein structure from protein data bank (PDB ID: 4BKX and 5ICN) 
and preparation of protein using ‘‘protein preparation wizard’’ in 
Maestro wizard v9.3 (Schrodinger, LLC, New York). The protein 
preparation process further comprised of two steps-first is the 
preparation of protein and second is a refinement of protein 
structure. The preparation step involved the addition of missing 
hydrogen atoms and missing side chains to the protein molecule. In 
the refinement step, the minimization of the protein molecule was 
achieved with the help of OPLS_2005 force field [23, 24]. After the 
preparation of protein, the receptor grid was produced for the active 
site using grid-receptor generation program. The ligands were 
drawn employing Ligprep module and docked with the help of SP 
(standard precision) and XP (extra precision) docking methods. The 
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protein-ligand binding affinities of Glide XP docking were analyzed 
novel scoring function GScore. The comparison of docking pose, 
coverage of contacts docked ligand with the co-crystallized 
structure, accuracy along with RSMD were the major parameter 
used for validation of molecular studies [25-28]. 
E-pharmacophore hypothesis generation 
The e-pharmacophore basically involved the structural and 
energetic data to find out the contact scoring using the scoring 
option of Glide XP [29]. It is a combined approach of structure and 
ligand-based 3D-QSAR technique. The e-pharmacophore hypothesis 
was generated using Maestro 9.3 [30-32]. 
RESULTS AND DISCUSSION 
Pharmacophore and atom based 3D QSAR modelling 
For the development of 3D-QSAR, we have set the active and inactive 
edge of biological data at 7.15 and 6.50, respectively. For QSAR 
analysis, 24 compounds were taken as a data set and out of these, 17 
and 7 compounds were allocated as training set and test set, 
respectively. These 24 molecules were clustered into active, 
moderately active and inactive based on their activity profile. The 
test compounds were selected as they really indicate the training 
set. The common pharmacophore hypotheses were developed using 
common pharmacophore identification methodology. The five 
featured pharmacophore hypotheses with a high value of survival 
score, the capability to express the complete binding space of 
molecules were selected and subjected to scoring function and top 
twelve common pharmacophore hypothesis (table 2) were selected 
for preparation of 3D QSAR model employing three PLS factors. 
The AADRR.356 common pharmacophore hypothesis was 
considered for 3D QSAR model development. The fitness, robustness 
and statistical validity of AADRR.356 QSAR models were analyzed 
and validated by standard deviation of the regression (SD) 0.1262, 
coefficient of determination (R2) 0.9588, F statistic (F) 100.7, 
statistical significance (P) 2.985e-009, stability value-0.2636, root-
mean-square error (RMSE) 0.1857, prediction coefficient (Q2) 
0.7261 and pearson-R-value 0.8552 (table 3). The fitness of 
AADRR.356 Common pharmacophore hypothesis was expressed in 
fig. 2 and table 4 along with observed and predicted activity. 
 
Table 2: Scoring results of the different hypotheses generated for pyrazole-based SAHA analogs 
ID Survival Survival–inactive Post-hoc Site Vector Volume Selectivity Matches 
ADDRR.848 3.651 1.3 3.651 0.93 0.998 0.719 1.653 5 
AADDR.1255 3.651 1.402 3.651 0.93 0.998 0.719 1.467 5 
ADHRR.411 3.631 1.281 3.631 0.89 0.998 0.74 1.814 5 
AADHR.1407 3.621 1.459 3.621 0.93 0.98 0.707 1.556 5 
ADDHR.680 3.62 1.372 3.621 0.95 0.989 0.678 1.759 5 
AAAHR.553 3.595 1.152 3.595 0.92 0.99 0.685 1.557 5 
DDHRR.590 3.565 1.225 3.565 0.88 0.977 0.703 2.145 5 
AAHRR.1185 3.52 1.231 3.52 0.83 0.99 0.698 1.785 5 
AADDH.315 3.484 1.21 3.484 0.88 0.953 0.652 1.409 5 
AAADH.396 3.461 1.052 3.461 0.86 0.942 0.654 1.272 5 
AADRR.356 3.406 1.35 3.406 0.78 0.954 0.667 1.454 5 
AAADR.427 3.396 1.228 3.396 0.78 0.934 0.681 1.322 5 
 
Table 3: Statistical results of a 3D-QSAR model developed using AADRR.356 common pharmacophore hypothesis for PLS factor 3 of 
pyrazole-based SAHA analogs 
ID PLS Factor SD R2 F P Stability RMSE Q2 Pearson-R 
AADRR.356 1 0.337 0.6606 29.2 7.318e-005 0.2618 0.2518 0.4964 0.7175 
2 0.2078 0.8796 51.2 3.657e-007 -0.2001 0.2702 0.4203 0.662 
3 0.1262 0.9588 100.7 2.985e-009 -0.2636 0.1857 0.7261 0.8552 
 
 
Fig. 2: The plot of observed activity versus predicted activity for 3D-QSAR model generated using common pharmacophore hypothesis: 
AADRR.356 (a) training set (b) test set. The graphical representations were obtained using Schrödinger software module 
 
Rajak et al. 





Fig. 3: Cubic pictorial representation of 3-D QSAR model based on ligand 1 (training set) for AADRR.356 common pharmacophore 
hypothesis (a) hydrogen bond donor features (b) hydrogen bond acceptor features (c) hydrophobic features. Blue colored cubes 
indicated favorable regions, while red colored cubes indicated unfavorable region for HDAC1 inhibitory activity. The graphical 
representations were obtained using Schrödinger software module 
 
Table 4: Pyrazole based SAHA analogs with predicted activity and fitness score 
Ligand name QSAR Set Activity Predicted activity Pharm set Fitness 
1 training 6.49 6.64 Inactive 2.19 
2 training 5.88 5.98 Inactive 2.08 
3 training 6.49 6.58 inactive 2.19 
4 test 6.66 6.60  2.19 
5 training 6.62 6.54  2.34 
6 test 6.71 7.02  2.44 
7 training 6.53 6.37  2.26 
8 test 6.47 6.55 inactive 2.25 
9 training 7.17 7.15 active 2.53 
10 training 6.94 6.79  2.14 
11 training 6.27 6.37 inactive 2.28 
12 training 7.48 7.35 active 2.36 
13 training 7.19 7.22 active 2.59 
14 test 6.42 6.57 inactive 2.3 
15 test 7.17 6.98 active 2.27 
16 training 7.07 7.26  2.69 
17 training 7.12 7.10  2.35 
18 test 7.46 7.37 active 3 
19 training 6.84 6.72  1.83 
20 training 6.14 6.04 inactive 2.1 
21 training 6.64 6.75  1.97 
22 test 6.63 6.36  1.53 
23 training 5.58 5.51 inactive 1.94 
24 training 5.6 5.69 inactive 1.19 
 
The evaluation of generated 3D-QSAR models was based on the 
various features, i.e., hydrogen bond donor, hydrogen bond acceptor 
and hydrophobic character. For the visualization of 3D-QSAR, the 
favourable and unfavourable features for biological activity has been 
presented in cube form as depicted in fig. 3(a,b,c). The blue cubes 
indicated favorable features, while red cube indicated unfavourable 
features. In the development of 3D-QSAR model, ligand 1 was 
selected as a training set to the best representation of hydrogen 
donor, hydrogen bond acceptor, hydrophobic and electronic 
characteristic predictions features as depicted in fig. 3(a,b,c). In 
AADRR.356 common pharmacophore hypothesis, the substitution of 
hydrogen bond donor around the blue region at A3 and A2 position 
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favored the HDAC1 inhibition activity, while H-bond donor around 
the red region at D5 position unfavored the HDAC1 inhibition 
activity (fig. 3a). Hydrogen bond acceptor or electron withdrawing 
group around the blue region at A2, A3, N atoms of pyrazole nucleus 
of R8 ring and R4 position of R9 ring favored the HDAC1 inhibitory 
activity (fig. 3b). The replacement of hydrophobic groups near the 
blue region at R4 position i.e., substitution of C6H5NH, C6H5, C6H5O, 
C6H5CH2O groups at R4 increased the HDAC1 inhibitory activity, 
while the substitution around the red region at R3 and R2 positions 
resulted in decreased HDAC1 inhibitory activity. 
Molecular docking study 
All structures were docked with HDAC1 proteins (PDB ID: 4BKX and 
5ICN) for examining the binding mode of compounds for HDAC 
inhibitory activity. The carbonyl oxygen of hydroxamic acid 
interacted with zinc atom and NH group interacted with GLY 149 in 
both the proteins in a similar manner. Compound 1 showed critical 
hydrophobic interaction with TYR 204 in 5ICN protein [fig. 4(c,d)] 
while showed hydrophobic interactions with HIE 28, PHE 150 and 
PHE 205 amino acids in 4BKX protein as reported in various studies 
[fig. 4(a,b)] [33-35]. 
E-pharmacophore studies 
The e-pharmacophoric features were developed for pyrazole 
analogues against 4BKX and 5ICN HDAC1 proteins. We have 
predicted for seven pharmacophoric sites, but four pharmacophoric 
sites were scored against 4BKX while five pharmacophoric features 
were scored against 5ICN. The pharmacophoric scores and 
generated corresponding features are described in table 5. These 
scores of pharmacophoric features revealed that hydrogen bonding 
of compounds with the receptor at A3 and D5 in both the proteins 
are important pharmacophores, While R8 in 4BKX based e-
pharmacophore and R7 and R8 in 5ICN based e-pharmacophores are 
essential for the hydrophobic environment (fig. 5). 
 
Table 5: Scores of e-pharmacophoric features applying glide XP docking 
Protein PDB ID Feature label Score Score source 
4BKX A3 -0.67 H-bond 
D5 -0.62 H-bond 
H6 -0.17 Phob En 
R8 -0.77 Ring Chemscore Hphobe 
5ICN H6 -0.29 Phob En 
A3 -0.24 H-bond 
D5 -0.15 H-Bond 
R7 -0.82 Ring Chemscore Hphobe 




Fig. 4: Docking of compound 1 on HDAC1 proteins (a) 2D binding representation of the compound 1 on HDAC1 (PDB ID: 4BKX) (b) Docked 
pose of compound 1 (green) with HDAC1 protein (PDB ID: 4BKX) (c) 2D binding representation of the compound 1 on HDAC1 (PDB ID: 
5ICN) (d) Docked pose of compound 1 (green) with HDAC1 protein (PDB ID: 5ICN). Pink dotted lines indicate hydrogen binding. The 
graphical representations were obtained using Schrödinger software module 
Rajak et al. 




Fig. 5: Pharmacophoric features of pyrazole derivatives in (a) 4BKX (b) 5ICN HDAC1 proteins using the e-pharmacophore script. 
Hydrogen bond acceptor (A3 = pink and D5 = magenta), hydrophobic aromatic rings (R8 and R7 = orange) and Phab En (H6 = green). The 
graphical representations were obtained using Schrödinger software module 
 
CONCLUSION 
Ligand and structure-based computer-aided drug design strategies 
i.e., Pharmacophore and atom based 3D-QSAR modelling, molecular 
docking and energetic based pharmacophore mapping, were applied 
to establish the structure-activity correlation of pyrazole-based 
SAHA analogs. Pharmacophoric model was developed by Phase 
module and e-pharmacophore mapping on compound 1. The 
pharmacophoric models were characterized by a set of points in 3D 
space, which correspond to a variety of chemical features which may 
assist non-covalent binding between the ligand molecule and its 
corresponding target receptor. The visualization of the 3D-QSAR 
model pointed out that the pyrazole nucleus played an important 
role in hydrophobic character in cap group responsible for 
recognition of active binding site in a protein molecule. Molecular 
docking studies indicated that all the pyrazole derivatives bind with 
HDAC1 proteins and the carbonyl oxygen of hydroxamic acid 
interacts with zinc atom and NH group interacts with GLY 149 in 
both the proteins in a similar manner. Compound 1 showed critical 
hydrophobic interaction with TYR 204 of 5ICN protein while 
showed interactions with HIE 28, PHE 150 and PHE 205 of 4BKX 
protein. It is anticipated that the results of these structure and 
ligand-based strategies could be employed for the precise design of 
novel pyrazole-based HDACi. 
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